Register or Sign in to Save this opportunity, or Send an Inquiry.
Innopharmax Inc. Taiwan flag Taiwan
Abstract ID:
INNOPHARMAX is leveraging the OralPAS® technology to develop Gemcitabine OralPAS®, a Phase 2 ready oral gemcitabine program with available data demonstrating \r\nStable disease in 12 patients having either advanced solid malignancies and/or malignant lympho
Send an Inquiry
Stable disease in 12 patients having either advanced solid malignancies and/or malignant lymphomas, nine (9) of whom were on study for ≥ three (3) months No dose limiting toxicities (DLTs) Low incidence of adverse events with the majority being mild-to-moderate (Grade 1 or Grade 2) Gemcitabine OralPAS® is protected by a robust intellectual property portfolio with granted patents providing protection for both the program as well as the underlying technology across the seven major markets GEMCITABINE (2\',2\'-difluorodeoxycytidine) is a fluorine- substituted deoxycytidine analog with a broad spectrum of antitumor activity. It is rapidly and extensively deaminated by cytidine deaminase to the inactive metabolite, 2\',2\'-difluorodeoxyuridine (dFdU). In order to enhance the bioavailability as well as the stability of gemcitabine via oral administration, INNOPHARMAX has applied OralPAS® technique on gemcitabine to prepare unique oral formulation. OralPAS® enhances the bioavailability of drugs through solubilization in the excipient matrix or interface and dispersion in the gastrointestinal tract. These characteristics result in faster drug release from nanoparticles in a reproducible manner, which can be designed further to make the release characteristics independent of the gastro-intestinal physiology and the fed/fasted state of the patient. Recently, several in-vitro and in-vivo studies (i.e. pilot tests in rats and dogs) have been done and study goals have been met.   The key advantages of OralPAS® include, but is not limited to Applications to both Class III and Class IV drug candidates Disperses drug-contained droplets into nano-size particles Increases solubilization and dissolution Protects against degradation Enhances oral absorption OralPAS® has numerous applications to include reformulating new chemical entities (NCEs) with solubility issues; developing generic drugs with high technology barriers to entry; as well as, reformulating known drugs in an effort to address unmet medical needs and/or increase patient compliance
Type of Business Relationship Sought
<p>To look for partners around the world to license out or co-develop Inno-D07001(Gemcitabine Oral)</p>
Last Updated Mar 2019
Technology Type THERAPEUTIC
Phase of Development PHASE 1

Opportunity Contact

Warning: include(js_message_scripts_n2.php) [function.include]: failed to open stream: No such file or directory in /home/pharmalicensing/public_html/detail.php on line 833

Warning: include() [function.include]: Failed opening 'js_message_scripts_n2.php' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/pharmalicensing/public_html/detail.php on line 833